Aplaviroc (INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines developed for the treatment of HIV infection. It was developed by GlaxoSmithKline.

In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations.

See also

  • CCR5 receptor antagonist

References

Further reading


Rescued aplaviroc activity in CCR5CCR2 (all ⌬ 2b) . Schematic

Molecular structure of SCHC, vicriviroc, TAK779, aplaviroc, 3bb and

Amoclav® 875 mg + 125 mg 20 St mit dem ERezept kaufen Shop Apotheke

Amoclav® 500 plus 20 St mit dem ERezept kaufen Shop Apotheke

Aplaviroc hydrochloride TargetMol